Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy

被引：16

作者：

French, Jacqueline A. ^{[1
,8
]}

Porter, Roger J. ^{[2
]}

Perucca, Emilio ^{[3
,4
]}

Brodie, Martin J. ^{[5
]}

Rogawski, Michael A. ^{[6
]}

Pimstone, Simon ^{[7
]}

Aycardi, Ernesto ^{[7
]}

Harden, Cynthia ^{[7
]}

Qian, Jenny ^{[7
]}

Luzon Rosenblut, Constanza ^{[7
]}

Kenney, Christopher ^{[7
]}

Beatch, Gregory N. ^{[7
]}

机构：

[1] NYU, Comprehens Epilepsy Ctr, New York, NY USA

[2] Univ Penn, Dept Neurol, Philadelphia, PA USA

[3] Univ Melbourne, Austin Hlth, Dept Med, Melbourne, Vic, Australia

[4] Monash Univ, Dept Neurosci, Melbourne, Vic, Australia

[5] Western Infirm & Associated Hosp, Univ Dept Med & Therapeut, Glasgow, Scotland

[6] Univ Calif Davis, Sch Med, Sacramento, CA USA

[7] Xenon Pharmaceut, Vancouver, BC, Canada

[8] NYU, Comprehens Epilepsy Ctr, 223 34th St, New York, NY 10016 USA

来源：

JAMA NEUROLOGY | 2023年 / 80卷 / 11期

关键词：

D O I：

10.1001/jamaneurol.2023.3542

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

QuestionIs the novel Kv7.2/Kv7.3 potassium channel opener XEN1101 effective in reducing the monthly seizure frequency in adults experiencing focal-onset seizures (FOSs) despite treatment with 1 to 3 baseline antiseizure medications (ASMs)?FindingsIn this phase 2b randomized clinical trial including 325 patients with FOSs, treatment with XEN1101 was associated with a statistically significant and robustly dose-dependent decrease in monthly seizure frequency and was generally well tolerated, with adverse effects similar to those of currently available ASMs.MeaningThe findings of this trial support the continued development of XEN1101 for the treatment of FOSs.

引用

页码：1145 / 1154

页数：10

共 50 条

[1] XEN1101, a novel potassium channel opener: hope or hype for adults with focal seizure
Fareed, Areeba
Sohail, Afra
Siddiqui, Wajeeha
Asif, Muhammad Iqbal
Ahmed, Tagwa Kalool Fadlalla
ANNALS OF MEDICINE AND SURGERY, 2024, 86 (05): : 2417 - 2419
[2] Phase 2b Efficacy and safety of XEN1101, a novel potassium channel opener, in adults with focal onset seizures (X-TOLE)
French, J.
Porter, R.
Perucca, E.
Brodie, M.
Rogawski, M.
Pimstone, S.
Aycardi, E.
Harden, C.
Xu, Y.
Rosenblut, C. Luzon
Kenney, C.
Beatch, G.
EPILEPSIA, 2022, 63 : 117 - 118
[3] Phase 2B Efficacy and Safety of XEN1101, a Novel Potassium Channel Modulator, In Adults with Focal Epilepsy (X-TOLE)
French, Jacqueline
Porter, Roger
Perucca, Emilio
Brodie, Martin
Rogawski, Michael A.
Pimstone, Simon
Aycardi, Ernesto
Harden, Cynthia
Xu, Yi
Rosenblut, Constanza Luzon
Kenney, Christopher
Beatch, Greg
NEUROTHERAPEUTICS, 2022, 19 (04) : 1427 - 1427
[4] Rapid onset of efficacy of XEN1101, a novel potassium channel opener, in adults with focal epilepsy: Results from a phase 2b study (X-TOLE)
Kenney, C.
French, J.
Porter, R.
Perucca, E.
Brodie, M.
Rogawski, M.
Harden, C.
Rosenblut, C. Luzon
Qian, J.
Leung, J.
Beatch, G.
EPILEPSIA, 2022, 63 : 136 - 136
[5] The Impact of Disease Severity on Efficacy from a Phase 2b Study of XEN1101, A Novel Potassium Channel Opener, in Adults With Focal Epilepsy (X-TOLE)
Kenney, Christopher
French, Jacqueline
Porter, Roger
Perucca, Emilio
Brodie, Martin
Rogawski, Michael A.
Harden, Cynthia
Qian, Jenny
Beatch, Greg
NEUROTHERAPEUTICS, 2022, 19 (04) : 1427 - 1428
[6] The impact of disease severity on efficacy from a Phase 2b study of XEN1101, a novel potassium channel opener, in adults with focal epilepsy (X-TOLE)
Kenney, C.
French, J.
Porter, R.
Perucca, E.
Brodie, M.
Rogawski, M.
Harden, C.
Rosenblut, C. Luzon
Qian, J.
Leung, J.
Beatch, G.
EPILEPSIA, 2022, 63 : 136 - 136
[7] Efficacy and Safety of XEN1101,aNovelPotassiumChannelOpener,in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial (vol 80, pg 1145, 2023)
不详
JAMA NEUROLOGY, 2024, 81 (02) : 200 - 200
[8] Depression and Anhedonia: Acute Preclinical Efficacy for XEN1101, a Differentiated Kv7 Potassium Channel Modulator
Cutts, Alison
Namdari, Rostam
Beatch, Greg
Weishaupt, Nina
Dean, Richard
Bechard, Jeff
Johnson, Jp
Empfield, James
Sherrington, Robin
NEUROTHERAPEUTICS, 2021, 18 (03) : 2143 - 2143
[9] XEN1101, a novel potassium channel modulator: interim data from an ongoing, long-term, open-label extension of a phase 2b study (X-TOLE) in adults with focal epilepsy
French, J.
Porter, R.
Perucca, E.
Brodie, M.
Rogawski, M. A.
Harden, C.
Qian, J.
Luzon-Rosenblut, C.
Kenney, C.
Beatch, G. N.
EPILEPSIA, 2023, 64 : 275 - 276
[10] XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, Open-Label Extension of a Phase 2b study (X-TOLE) in Adults with Focal Epilepsy
French, Jacqueline
Porter, Roger
Perucca, Emilio
Brodie, Martin
Rogawski, Michael
Harden, Cynthia
Qian, Jenny
Luzon-Rosenblut, Constanza
Kenney, Christopher
Beatch, Gregory
NEUROLOGY, 2023, 100 (17)

← 1 2 3 4 5 →